Kiniksa (KNSA) COO 10b5-1 Sale and Option Exercise Reduces Holdings
Rhea-AI Filing Summary
Kiniksa Pharmaceuticals insider transactions by COO Eben Tessari show a mix of purchases and sales executed under a 10b5-1 plan. The reporting person exercised 6,500 vested options at an exercise price of $8.83 on 08/18/2025, acquiring 6,500 Class A ordinary shares. On the same date the reporting person sold 16,100 shares at a weighted-average price of $33.77 and an additional 100 shares at $34.44, reducing beneficial ownership to 40,215 shares. The Form 4 notes the trades were effected pursuant to a 10b5-1 plan executed April 29, 2024, and the option is fully vested and exercisable through 09/16/2029.
Positive
- Exercise of 6,500 vested options at $8.83 indicates the reporting person converted lower-cost compensation into stock
- Transactions executed under a 10b5-1 plan, providing prearranged, documented trading that reduces concerns about opportunistic timing
Negative
- Sale of 16,200 shares (16,100 at weighted-average $33.77 and 100 at $34.44) materially reduced beneficial ownership to 40,215 shares
- Significant disposition size by an executive could be viewed negatively by some investors absent further context on remaining stake or reasons for sale
Insights
TL;DR: Insider exercised options cheaply and sold a larger block at much higher market prices under a 10b5-1 plan; results are routine but notable for size.
The reporting person exercised 6,500 options at $8.83 and sold 16,200 shares at a weighted-average above $33.7, locking in substantial gross proceeds relative to exercise cost. Because the transactions were made under a documented 10b5-1 plan, timing appears pre-arranged, reducing concerns about opportunistic trading on material nonpublic information. The net effect lowered beneficial ownership to 40,215 shares, which is meaningful for an executive-level holder but not dispositive without position size or % of outstanding shares.
TL;DR: Transactions comply with 10b5-1 disclosure; the mix of exercise plus sales is governance-normal but merits tracking.
The Form 4 discloses use of a 10b5-1 plan executed April 29, 2024, which provides an affirmative defense for trading plans. The filing clearly states the option is fully vested and the sales were executed through a broker-dealer with a disclosed weighted-average sale price. From a governance perspective, documentation and transparent pricing disclosures are appropriate; no governance violations or unexplained exceptions appear in the filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Share Option | 6,500 | $0.00 | -- |
| Exercise | Class A Ordinary Share | 6,500 | $8.83 | $57K |
| Sale | Class A Ordinary Share | 16,100 | $33.77 | $544K |
| Sale | Class A Ordinary Share | 100 | $34.44 | $3K |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.41 and $34.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. The option is fully vested and exercisable.
